Search

Your search keyword '"Filippatos, Gerasimos"' showing total 2,373 results
Start Over Author "Filippatos, Gerasimos" Search Limiters Full Text
2,373 results on '"Filippatos, Gerasimos"'

1. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.

Author

Filippatos, Gerasimos, Anker, Stefan, August, Phyllis, Coats, Andrew, Januzzi, James, Mankovsky, Boris, Rossing, Peter, Ruilope, Luis, Pitt, Bertram, Sarafidis, Pantelis, Teerlink, John, Kapelios, Chris, Gebel, Martin, Brinker, Meike, Joseph, Amer, Lage, Andrea, Bakris, George, and Agarwal, Rajiv

Subjects
All-cause mortality, Cardiovascular mortality, Chronic kidney disease, Finerenone, Non-steroidal MRA, Type 2 diabetes, Humans, Middle Aged, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Mineralocorticoid Receptor Antagonists, Renal Insufficiency, Chronic, Heart Failure, Death, Sudden, Cardiac
Abstract

AIMS: Finerenone reduces the risk of cardiovascular events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). We investigated the causes of mortality in the FIDELITY population. METHODS AND RESULTS: The FIDELITY prespecified pooled data analysis from FIDELIO-DKD and FIGARO-DKD excluded patients with heart failure and reduced ejection fraction. Outcomes included intention-to-treat and prespecified on-treatment analyses of the risk of all-cause and cardiovascular mortality. Of 13 026 patients [mean age, 64.8 years; mean estimated glomerular filtration rate (eGFR), 57.6 mL/min/1.73 m2], 99.8% were on renin-angiotensin system inhibitors. Finerenone reduced the incidence of all-cause and cardiovascular mortality vs. placebo (8.5% vs. 9.4% and 4.9% vs. 5.6%, respectively) and demonstrated significant on-treatment reductions [hazard ratio (HR), 0.82; 95% confidence interval (CI), 0.70-0.96; P = 0.014 and HR, 0.82; 95% CI, 0.67-0.99; P = 0.040, respectively]. Cardiovascular-related mortality was most common, and finerenone lowered the incidence of sudden cardiac death vs. placebo [1.3% (incidence rate 0.44/100 patient-years) vs. 1.8% (0.58/100 patient-years), respectively; HR, 0.75; 95% CI, 0.57-0.996; P = 0.046]. The effects of finerenone on mortality were similar across all Kidney Disease: Improving Global Outcomes risk groups. Event probability with finerenone at 4 years was consistent irrespective of baseline urine albumin-to-creatinine ratio, but seemingly more pronounced in patients with higher baseline eGFR. CONCLUSION: In FIDELITY, finerenone significantly reduced the risk of all-cause and cardiovascular mortality vs. placebo in patients with T2D across a broad spectrum of CKD stages while on treatment, as well as sudden cardiac death in the intention-to-treat population. CLINICAL TRIALS REGISTRATION: FIDELIO-DKD and FIGARO-DKD are registered with ClinicalTrials.gov, numbers NCT02540993 and NCT02545049, respectively (funded by Bayer AG).

Published
2023

2. Implications of worsening renal function before hospitalization for acute heart failure

Author

Wettersten, Nicholas, Duff, Stephen, Horiuchi, Yu, Veldhuisen, Dirk J, Mueller, Christian, Filippatos, Gerasimos, Nowak, Richard, Hogan, Christopher, Kontos, Michael C, Cannon, Chad M, Müeller, Gerhard A, Birkhahn, Robert, Taub, Pam, Vilke, Gary M, McDonald, Kenneth, Mahon, Niall, Nuñez, Julio, Briguori, Carlo, Passino, Claudio, Maisel, Alan, Murray, Patrick T, and Ix, Joachim H

Subjects
Kidney Disease, Heart Disease, Clinical Research, Cardiovascular, Patient Safety, Renal and urogenital, Humans, Kidney, Creatinine, Acute Disease, Biomarkers, Heart Failure, Hospitalization, Acute heart failure, Acute kidney injury, Cardiorenal syndrome, Cardiorespiratory Medicine and Haematology
Abstract

AimsKidney function changes dynamically during AHF treatment, but risk factors for and consequences of worsening renal function (WRF) at hospital admission are uncertain. We aimed to determine the significance of WRF at admission for acute heart failure (AHF).Methods and resultsWe evaluated a subgroup of 406 patients from The Acute Kidney Injury Neutrophil gelatinase-associated lipocalin Evaluation of Symptomatic heart failure Study (AKINESIS) who had serum creatinine measurements available within 3 months before and at the time of admission. Admission WRF was primarily defined as a 0.3 mg/dL or 50% creatinine increase from preadmission. Alternative definitions evaluated were a ≥0.5 mg/dL creatinine increase, ≥25% glomerular filtration rate decrease, and an overall change in creatinine. Predictors of admission WRF were evaluated. Outcomes evaluated were length of hospitalization, a composite of adverse in-hospital events, and the composite of death or HF readmission at 30, 90, and 365 days. Biomarkers' prognostic ability for these outcomes were evaluated in patients with admission WRF. One-hundred six patients (26%) had admission WRF. These patients had features of more severe AHF with lower blood pressure, higher BUN, and lower serum sodium concentrations at admission. Higher BNP (odds ratio [OR] per doubling 1.16-1.28, 95% confidence interval [CI] 1.00-1.55) and lower diastolic blood pressure (OR 0.97-0.98, 95% CI 0.96-0.99) were associated with a higher odds for the three definitions of admission WRF. The primary WRF definition was not associated with a longer hospitalization, but alternative WRF definitions were (1.3 to 1.6 days longer, 95% CI 1.0-2.2). WRF across definitions was not associated with a higher odds of adverse in-hospital events or a higher risk of death or HF readmission. In the subset of patients with WRF, biomarkers were not prognostic for any outcome.ConclusionsAdmission WRF is common in AHF patients and is associated with an increased length of hospitalization, but not adverse in-hospital events, death, or HF readmission. Among those with admission WRF, biomarkers did not risk stratify for adverse events.

Published
2023

3. Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure

Author

Usman, Muhammad Shariq, Khan, Muhammad Shahzeb, Fonarow, Gregg C, Greene, Stephen J, Friede, Tim, Vaduganathan, Muthiah, Filippatos, Gerasimos, Coats, Andrew J Stewart, Anker, Stefan D, and Butler, Javed

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cardiovascular, Heart Disease, Good Health and Well Being, Glucose, Heart Failure, Humans, Sodium, Sodium-Glucose Transporter 2 Inhibitors, Symporters, Fragility index, Robustness, Sodium-glucose co-transporter 2 inhibitors, Cardiac failure, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

AimsRecent trials have evaluated sodium-glucose co-transporter 2 inhibitors in patients with heart failure (HF). We sought to assess the robustness of findings from these trials using the fragility index (FI).Methods and resultsFragility index is defined as the minimum number of patients that must be moved from the 'non-event' to the 'event' group to turn a statistically significant result to non-significant. In addition to FI, fragility quotient [(FQ); FI divided by the sample size] was calculated to assess the proportion of events that must be moved to change the significance. For statistically non-significant outcomes, reverse fragility index (RFI) and reverse fragility quotient (RFQ) were calculated. Robustness of findings after pooling data from all three trials was also assessed. A robust reduction in first HF hospitalization or cardiovascular mortality was seen with dapagliflozin (FI = 62 and FQ = 0.013), empagliflozin (FI = 50 and FQ = 0.013), and sotagliflozin (FI = 60 and FQ = 0.049). Dapagliflozin nominally improved all-cause and cardiovascular mortality, with modest FI (n = 8 and 5) and FQ (0.002 and 0.001). Empagliflozin and sotagliflozin did not demonstrate statistically significant reductions in all-cause mortality, with modest RFI (empagliflozin: RFI = 26 and RFQ = 0.007; sotagliflozin: RFI = 6 and RFQ = 0.005). A similar trend was seen with cardiovascular mortality (empagliflozin: RFI = 24 and RFQ = 0.006; sotagliflozin: RFI = 7 and RFQ = 0.006). Upon meta-analysis, the result for first HF hospitalization or cardiovascular mortality was robust (FI = 95 and FQ = 0.010). The reductions in all-cause (FI = 12 and FQ = 0.001) and cardiovascular mortality (FI = 9 and FQ = 0.001), while statistically significant, were fragile.ConclusionImprovement in the composite outcome of first HF hospitalization or cardiovascular death was highly concordant and robust across sodium-glucose co-transporter 2 inhibitor trials. In contrast, secondary endpoints of all-cause and cardiovascular mortality were statistically fragile, underscoring the need to power trials for mortality to fully understand the benefit of therapies on fatal events.

Published
2022

4. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

Author

Rosano, Giuseppe, Ponikowski, Piotr, Vitale, Cristiana, Anker, Stefan D., Butler, Javed, Fabien, Vincent, Filippatos, Gerasimos, Kirwan, Bridget-Anne, Macdougall, Iain C., Metra, Marco, Ruschitzka, Frank, Kumpeson, Vasuki, Goehring, Udo-Michael, van der Meer, Peter, and Jankowska, Ewa A.

Published
2023
Full Text
View/download PDF

5. Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction

Author

Tomasoni, Daniela, Fonarow, Gregg C, Adamo, Marianna, Anker, Stefan D, Butler, Javed, Coats, Andrew JS, Filippatos, Gerasimos, Greene, Stephen J, McDonagh, Theresa A, Ponikowski, Piotr, Rosano, Giuseppe, Seferovic, Petar, Vaduganathan, Muthiah, Voors, Adriaan A, and Metra, Marco

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Patient Safety, Diabetes, Cardiovascular, Heart Disease, Clinical Research, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Development of treatments and therapeutic interventions, Metabolic and endocrine, Good Health and Well Being, Diabetes Mellitus, Type 2, Glucose, Heart Failure, Humans, Quality of Life, Sodium, Sodium-Glucose Transporter 2 Inhibitors, Stroke Volume, Symporters, Heart failure with reduced ejection fraction, Sodium-glucose co-transporter 2 inhibitors, Dapagliflozin, Empagliflozin, Sotagliflozin, Medical therapy, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have recently been recommended as a foundational therapy for patients with heart failure (HF) and reduced ejection fraction (HFrEF) because of their favourable effects on mortality, clinical events and quality of life. While clinical practice guidelines have recommended dapagliflozin or empagliflozin in all patients with HFrEF, or sotagliflozin in those with HFrEF and concomitant diabetes, the timing and practical integration of these drugs in clinical practice is less well defined. We propose that these drugs are candidates for early, upfront administration to patients with newly diagnosed HFrEF and for patients hospitalized with HF. Growing evidence has established early benefits, with clinically meaningful reductions in clinical events that reach statistical significance within days to weeks, following dapagliflozin, empagliflozin or, in diabetic patients, sotagliflozin initiation. Secondly, although major clinical trials have tested these drugs in patients already receiving background HF therapy, secondary analyses showed that their efficacy is independent of that. Third, SGLT2 inhibitors are generally safe and well tolerated, with clinical trial data reporting minimal effects on blood pressure, glycaemia-related adverse events, and no excess in acute kidney injury. Rather, they exert renal protective effects and reduce risk of hyperkalaemia, properties that favour initiation, tolerance and persistence of renin-angiotensin system inhibitors and mineralocorticoid receptor antagonists. This review supports the early initiation of dapagliflozin and empagliflozin (or sotagliflozin limited to patients with diabetes) to rapidly improve clinical outcome and quality of life of HFrEF patients.

Published
2022

6. Implementation of a cardiogenic shock team in a tertiary academic center

Author

Karamasis, Grigoris V., Polyzogopoulou, Effie, Varlamos, Charalampos, Frantzeskaki, Frantzeska, Dragona, Vassiliki-Maria, Boultadakis, Antonios, Bistola, Vasiliki, Fountoulaki, Katerina, Pappas, Christos, Kolokathis, Fotios, Pavlopoulos, Dionysios, Toumpoulis, Ioannis K., Kollias, Vasilios D., Farmakis, Dimitrios, Rallidis, Loukianos S., Angouras, Dimitrios C., Tsangaris, Iraklis, Parissis, John T., and Filippatos, Gerasimos

Published
2024
Full Text
View/download PDF

7. Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study

Author

Gerhardt, Teresa, Gerhardt, Louisa M S, Ouwerkerk, Wouter, Roth, Gregory A, Dickstein, Kenneth, Collins, Sean P, Cleland, John G F, Dahlstrom, Ulf, Tay, Wan Ting, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V, Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Filippatos, Gerasimos, Lam, Carolyn S P, Tromp, Jasper, and Angermann, Christiane E

Published
2023
Full Text
View/download PDF

8. Cardiorenal multimorbidity in hospitalized cardiology patients: The Hellenic Cardiorenal Morbidity Snapshot (HECMOS) study

Author

Leontsinis, Ioannis, Farmakis, Dimitrios, Avramidis, Dimitrios, Andrikou, Eirini, Valatsou, Angeliki, Gartzonikas, Elias, Doundoulakis, Ioannis, Zarifis, Ioannis, Karpouzis, Ioannis, Kafkala, Kristalenia, Kouvelas, Nikos, Kourek, Christos, Koufou, Eleni, Kochiadakis, George, Kifnidis, Konstantinos, Liori, Sotiria, Manolis, George, Marketou, Maria, Moschos, Nikitas, Bampatsias, Dimitrios, Bibis, George, Bonou, Maria, Naka, Aikaterini, Davlouros, Periklis, Ntalakouras, Ioannis, Papakonstantinou, Panteleimon Ε., Pappa, Evgenia, Patsilinakos, Sotirios, Plaitis, Aristeidis, Sideris, Antonios, Sideris, Skevos, Skoularigis, John, Stamatelopoulos, Kimon, Stefanou, Garyfallia, Tziakas, Dimitrios, Chatzieleftheriou, Christos, Chrysochoou, Christina, Filippatos, Gerasimos, and Tsioufis, Costas

Published
2023
Full Text
View/download PDF

10. Discontinuation and non‐publication of heart failure randomized controlled trials: a call to publish all trial results

Author

Khan, Muhammad Shahzeb, Shahid, Izza, Asad, Nava, Greene, Stephen J, Khan, Safi U, Doukky, Rami, Metra, Marco, Anker, Stefan D, Filippatos, Gerasimos S, Fonarow, Gregg C, and Butler, Javed

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Heart Disease, Clinical Trials and Supportive Activities, Cardiovascular, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Cross-Sectional Studies, Heart Failure, Humans, Randomized Controlled Trials as Topic, Heart failure, Clinical trials, Discontinuation, Non-publication, Enrolment, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

AimsDiscontinuation or non-publication of trials may hinder scientific progress and violates the commitment made to research participants. We sought to identify the prevalence of discontinuation and non-publication of heart failure (HF) clinical trials.Methods and resultsWe conducted a cross-sectional search of ClinicalTrials.gov to identify all completed and discontinued HF clinical trials. We limited our search to only include trials that were completed by 31 December 2017. Trials were investigated to identify reasons for discontinuation. Informative termination was defined as trial termination due to safety or efficacy concerns. Data pertaining to the trial phase, funding, intervention, enrolment, and trial completion date were extracted for each trial. A total of 572 trials were included. Of these, 21% (n = 118) were discontinued before completion. Patient accrual was the most frequently cited reason (n = 42; 36%) for trial discontinuation, followed by informative termination (n = 16; 14%) and funding (n = 14; 12%). Overall, 24 780 patients were enrolled in trials that were terminated. Of trials that were completed and not terminated, nearly one-third (n = 131/454; 29%) were not published. Seventy-nine (24%) trials were published within 12 months, 192 (59%) within 24 months, and 252 (78%) trials within 36 months.ConclusionsDiscontinuation and non-publication of HF trials is common. This raises ethical concerns towards participants who volunteer for research and are exposed to potential risks, inconvenience, and discomfort without furthering scientific progress.

Published
2021

11. Global Variations According to Sex in Patients Hospitalized for Heart Failure in the REPORT-HF Registry

Author

Tromp, Jasper, Ezekowitz, Justin A., Ouwerkerk, Wouter, Chandramouli, Chanchal, Yiu, Kai Hang, Angermann, Christiane E., Dahlstrom, Ulf, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V., Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Dickstein, Kenneth, Collins, Sean P., Filippatos, Gerasimos, Cleland, John G.F., and Lam, Carolyn S.P.

Published
2023
Full Text
View/download PDF

13. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

Author

Anker, Stefan D., Butler, Javed, Usman, Muhammad Shariq, Filippatos, Gerasimos, Ferreira, João Pedro, Bocchi, Edimar, Böhm, Michael, Rocca, Hans Pieter Brunner-La, Choi, Dong-Ju, Chopra, Vijay, Chuquiure, Eduardo, Giannetti, Nadia, Gomez-Mesa, Juan Esteban, Janssens, Stefan, Januzzi, James L., González-Juanatey, José R., Merkely, Bela, Nicholls, Stephen J., Perrone, Sergio V., Piña, Ileana L., Ponikowski, Piotr, Senni, Michele, Sim, David, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Tsutsui, Hiroyuki, Verma, Subodh, Vinereanu, Dragos, Zhang, Jian, Iwata, Tomoko, Schnee, Janet M., Brueckmann, Martina, Pocock, Stuart J., and Zannad, Faiez

Published
2022
Full Text
View/download PDF

14. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations

Author

Usman, Muhammad Shariq, Siddiqi, Tariq Jamal, Anker, Stefan D., Bakris, George L., Bhatt, Deepak L., Filippatos, Gerasimos, Fonarow, Gregg C., Greene, Stephen J., Januzzi, James L., Jr, Khan, Muhammad Shahzeb, Kosiborod, Mikhail N., McGuire, Darren K., Piña, Ileana L., Rosenstock, Julio, Vaduganathan, Muthiah, Verma, Subodh, Zieroth, Shelley, and Butler, Javed

Published
2023
Full Text
View/download PDF

17. Loop Diuretic Prescription and 30-Day Outcomes in Older Patients With Heart Failure

Author

Faselis, Charles, Arundel, Cherinne, Patel, Samir, Lam, Phillip H, Gottlieb, Stephen S, Zile, Michael R, Deedwania, Prakash, Filippatos, Gerasimos, Sheriff, Helen M, Zeng, Qing, Morgan, Charity J, Wopperer, Samuel, Nguyen, Tran, Allman, Richard M, Fonarow, Gregg C, and Ahmed, Ali

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Aging, Cardiovascular, Clinical Research, Heart Disease, Aged, Aged, 80 and over, Cohort Studies, Female, Heart Failure, Humans, Male, Sodium Potassium Chloride Symporter Inhibitors, Time Factors, Treatment Outcome, heart failure, loop diuretics, outcomes, Cardiorespiratory Medicine and Haematology, Public Health and Health Services, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

BackgroundHeart failure (HF) is a major source of morbidity and mortality. Fluid retention and shortness of breath are its cardinal manifestations for which loop diuretics are used. Although their usefulness is well accepted, less is known about their role in improving clinical outcomes.ObjectivesThe purpose of this study was to determine the relationship between loop diuretics and clinical outcomes in patients with HF.MethodsOf the 25,345 older patients hospitalized for HF in the Medicare-linked OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry, 9,866 (39%) received no pre-admission diuretics. The study excluded 1,083 patients receiving dialysis and 847 discharged on thiazide diuretics. Of the remaining 7,936 patients, 5,568 (70%) were prescribed loop diuretics at discharge. Using propensity scores for receipt of loop diuretics estimated for each of the 7,936 patients, a matched cohort of 2,191 pairs of patients was assembled balanced on 74 baseline characteristics. Hazard ratios (HRs) and 95% confidence intervals (CIs) for outcomes were estimated in the matched cohort.ResultsMatched patients (n = 4,382) had a mean age of 78 years, 54% were women, and 11% were African American. The 30-day all-cause mortality occurred in 4.9% (107 of 2,191) and 6.6% (144 of 2,191) of patients in the loop diuretic and no loop diuretic groups, respectively (HR when the use of loop diuretics was compared with nonuse: 0.73; 95% CI: 0.57 to 0.94; p = 0.016). Patients in the loop diuretic group had a significantly lower risk of 30-day HF readmission (HR: 0.79; 95% CI: 0.63 to 0.99; p = 0.037) but not of 30-day all-cause readmission (HR: 0.89; 95% CI: 0.79 to 1.01; p = 0.081). None of the associations was statistically significant during 60 days of follow-up.ConclusionsHospitalized older patients not taking diuretics prior to hospitalization for HF decompensation who received a discharge prescription for loop diuretics had significantly better 30-day clinical outcomes than those not discharged on loop diuretics. These findings provide new information about short-term clinical benefits associated with loop diuretic use in HF.

Published
2020

18. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Author

Anker, Stefan D, Butler, Javed, Khan, Muhammad Shahzeb, Abraham, William T, Bauersachs, Johann, Bocchi, Edimar, Bozkurt, Biykem, Braunwald, Eugene, Chopra, Vijay K, Cleland, John G, Ezekowitz, Justin, Filippatos, Gerasimos, Friede, Tim, Hernandez, Adrian F, Lam, Carolyn SP, Lindenfeld, JoAnn, McMurray, John JV, Mehra, Mandeep, Metra, Marco, Packer, Milton, Pieske, Burkert, Pocock, Stuart J, Ponikowski, Piotr, Rosano, Giuseppe MC, Teerlink, John R, Tsutsui, Hiroyuki, Van Veldhuisen, Dirk J, Verma, Subodh, Voors, Adriaan A, Wittes, Janet, Zannad, Faiez, Zhang, Jian, Seferovic, Petar, and Coats, Andrew JS

Subjects
Clinical Research, Patient Safety, Clinical Trials and Supportive Activities, Cardiovascular, Heart Disease, Prevention, Good Health and Well Being, Betacoronavirus, COVID-19, Clinical Trials as Topic, Coronavirus Infections, Europe, Heart Failure, Humans, Informed Consent, Pandemics, Patient Selection, Pneumonia, Viral, Research Design, SARS-CoV-2, Heart failure, Clinical trials, Coronavirus, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has important implications for the safety of participants in clinical trials and the research staff caring for them and, consequently, for the trials themselves. Patients with heart failure may be at greater risk of infection with COVID-19 and the consequences might also be more serious, but they are also at risk of adverse outcomes if their clinical care is compromised. As physicians and clinical trialists, it is our responsibility to ensure safe and effective care is delivered to trial participants without affecting the integrity of the trial. The social contract with our patients demands no less. Many regulatory authorities from different world regions have issued guidance statements regarding the conduct of clinical trials during this COVID-19 crisis. However, international trials may benefit from expert guidance from a global panel of experts to supplement local advice and regulations, thereby enhancing the safety of participants and the integrity of the trial. Accordingly, the Heart Failure Association of the European Society of Cardiology on 21 and 22 March 2020 conducted web-based meetings with expert clinical trialists in Europe, North America, South America, Australia, and Asia. The main objectives of this Expert Position Paper are to highlight the challenges that this pandemic poses for the conduct of clinical trials in heart failure and to offer advice on how they might be overcome, with some practical examples. While this panel of experts are focused on heart failure clinical trials, these discussions and recommendations may apply to clinical trials in other therapeutic areas.

Published
2020

19. Hepatorenal dysfunction identifies high‐risk patients with acute heart failure: insights from the RELAX‐AHF trial

Author

Biegus, Jan, Demissei, Biniyam, Postmus, Douwe, Cotter, Gad, Davison, Beth A, Felker, G Michael, Filippatos, Gerasimos, Gimpelewicz, Claudio, Greenberg, Barry, Metra, Marco, Severin, Thomas, Teerlink, John R, Voors, Adriaan A, and Ponikowski, Piotr

Subjects
Cardiovascular, Acute Disease, Aged, Aged, 80 and over, Bilirubin, Creatinine, Female, Heart Failure, Humans, Kidney Diseases, Liver Diseases, Male, Middle Aged, Prognosis, Severity of Illness Index, Acute heart failure, Liver dysfunction, Kidney dysfunction, MELD-XI score, Cardiorespiratory Medicine and Haematology
Abstract

AimsEpisodes of acute heart failure (AHF) may lead to end-organ dysfunction. In this post hoc analysis of the Relaxin in Acute Heart Failure trial, we used the MELD-XI (Model of End-Stage Liver Dysfunction) score to examine hepatorenal dysfunction in patients with AHF.Methods and resultsOn admission, the MELD-XI score was elevated (abnormal) in 918 (82%) patients, with 638 (57%) having isolated renal dysfunction (creatinine > 1 mg/dL), 73 (6.5%) isolated liver dysfunction (bilirubin > 1 mg/dL), and 207 (18.5%) coexisting dysfunction of the kidneys and the liver (both creatinine and bilirubin > 1 mg/dL). The percentage of patients with elevated MELD-XI score remained constant through a 60 day follow-up, as we observed a gradual decrease of liver dysfunction prevalence, counterbalanced by an increase in renal dysfunction. Serelaxin treatment was associated with a lower MELD-XI score on Day 2 and Day 5 (both P

Published
2019

21. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis

Author

Filippatos, Gerasimos, Ponikowski, Piotr, Farmakis, Dimitrios, Anker, Stefan D., Butler, Javed, Fabien, Vincent, Kirwan, Bridget-Anne, Macdougall, Iain C., Metra, Marco, Rosano, Giuseppe, Ruschitzka, Frank, van der Meer, Peter, Waechter, Sandra, and Jankowska, Ewa A.

Published
2023
Full Text
View/download PDF

23. Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE‐HF2 trial and comparison to COAPT and MITRA‐FR trials

Author

Anker, Stefan D., primary, Friede, Tim, additional, von Bardeleben, Ralph Stephan, additional, Butler, Javed, additional, Khan, Muhammad Shahzeb, additional, Diek, Monika, additional, Heinrich, Jutta, additional, Geyer, Martin, additional, Placzek, Marius, additional, Ferrari, Roberto, additional, Abraham, William T., additional, Alfieri, Ottavio, additional, Auricchio, Angelo, additional, Bayes‐Genis, Antoni, additional, Cleland, John G.F., additional, Filippatos, Gerasimos, additional, Gustafsson, Finn, additional, Haverkamp, Wilhelm, additional, Kelm, Malte, additional, Kuck, Karl‐Heinz, additional, Landmesser, Ulf, additional, Maggioni, Aldo P., additional, Metra, Marco, additional, Ninios, Vlasis, additional, Petrie, Mark C., additional, Rassaf, Tienush, additional, Ruschitzka, Frank, additional, Schäfer, Ulrich, additional, Schulze, P. Christian, additional, Spargias, Konstantinos, additional, Vahanian, Alec, additional, Zamorano, Jose Luis, additional, Zeiher, Andreas, additional, Karakas, Mahir, additional, Koehler, Friedrich, additional, Lainscak, Mitja, additional, Öner, Alper, additional, Mezilis, Nikolaos, additional, Theofilogiannakos, Efstratios K, additional, Ninios, Ilias, additional, Chrissoheris, Michael, additional, Kourkoveli, Panagiota, additional, Papadopoulos, Konstantinos, additional, Smolka, Grzegorz, additional, Wojakowski, Wojciech, additional, Reczuch, Krzysztof, additional, Pinto, Fausto J., additional, Zmudka, Krzysztof, additional, Kalarus, Zbigniew, additional, Adamo, Marianna, additional, Santiago‐Vacas, Evelyn, additional, Ruf, Tobias Friedrich, additional, Gross, Michael, additional, Tongers, Joern, additional, Hasenfuß, Gerd, additional, Schillinger, Wolfgang, additional, and Ponikowski, Piotr, additional

Published
2024
Full Text
View/download PDF

24. Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESC

Author

Rosano, Giuseppe M.C., primary, Stolfo, Davide, additional, Anderson, Lisa, additional, Abdelhamid, Magdy, additional, Adamo, Marianna, additional, Bauersachs, Johann, additional, Bayes‐Genis, Antoni, additional, Böhm, Michael, additional, Chioncel, Ovidiu, additional, Filippatos, Gerasimos, additional, Hill, Loreena, additional, Lainscak, Mitja, additional, Lambrinou, Ekaterini, additional, Maas, Angela H.E.M., additional, Massouh, Angela R., additional, Moura, Brenda, additional, Petrie, Mark C., additional, Rakisheva, Amina, additional, Ray, Robin, additional, Savarese, Gianluigi, additional, Skouri, Hadi, additional, Van Linthout, Sophie, additional, Vitale, Cristiana, additional, Volterrani, Maurizio, additional, Metra, Marco, additional, and Coats, Andrew J.S., additional

Published
2024
Full Text
View/download PDF

25. Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial

Author

Solomon, Scott D., primary, Ostrominski, John W., additional, Vaduganathan, Muthiah, additional, Claggett, Brian, additional, Jhund, Pardeep S., additional, Desai, Akshay S., additional, Lam, Carolyn S.P., additional, Pitt, Bertram, additional, Senni, Michele, additional, Shah, Sanjiv J., additional, Voors, Adriaan A., additional, Zannad, Faiez, additional, Abidin, Imran Zainal, additional, Alcocer‐Gamba, Marco Antonio, additional, Atherton, John J., additional, Bauersachs, Johann, additional, Ma, Chang‐Sheng, additional, Chiang, Chern‐En, additional, Chioncel, Ovidiu, additional, Chopra, Vijay, additional, Comin‐Colet, Josep, additional, Filippatos, Gerasimos, additional, Fonseca, Cândida, additional, Gajos, Grzegorz, additional, Goland, Sorel, additional, Goncalvesová, Eva, additional, Kang, Seok‐Min, additional, Katova, Tzvetana, additional, Kosiborod, Mikhail N., additional, Latkovskis, Gustavs, additional, Lee, Alex Pui‐Wai, additional, Linssen, Gerard C.M., additional, Llamas‐Esperón, Guillermo, additional, Mareev, Vyacheslav, additional, Martinez, Felipe A., additional, Melenovský, Vojtěch, additional, Merkely, Béla, additional, Nodari, Savina, additional, Petrie, Mark C., additional, Saldarriaga, Clara Inés, additional, Saraiva, Jose Francisco Kerr, additional, Sato, Naoki, additional, Schou, Morten, additional, Sharma, Kavita, additional, Troughton, Richard, additional, Udell, Jacob A., additional, Ukkonen, Heikki, additional, Vardeny, Orly, additional, Verma, Subodh, additional, von Lewinski, Dirk, additional, Voronkov, Leonid G., additional, Yilmaz, Mehmet Birhan, additional, Zieroth, Shelley, additional, Lay‐Flurrie, James, additional, van Gameren, Ilse, additional, Amarante, Flaviana, additional, Viswanathan, Prabhakar, additional, and McMurray, John J.V., additional

Published
2024
Full Text
View/download PDF

26. Dietary sodium and fluid intake in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC

Author

Mullens, Wilfried, primary, Damman, Kevin, additional, Dhont, Sebastiaan, additional, Banerjee, Debasish, additional, Bayes‐Genis, Antoni, additional, Cannata, Antonio, additional, Chioncel, Ovidiu, additional, Cikes, Maja, additional, Ezekowitz, Justin, additional, Flammer, Andreas J., additional, Martens, Pieter, additional, Mebazaa, Alexandre, additional, Mentz, Robert J., additional, Miró, Òscar, additional, Moura, Brenda, additional, Nunez, Julio, additional, Ter Maaten, Jozine M., additional, Testani, Jeffrey, additional, van Kimmenade, Roland, additional, Verbrugge, Frederik H., additional, Metra, Marco, additional, Rosano, Giuseppe M.C., additional, and Filippatos, Gerasimos, additional

Published
2024
Full Text
View/download PDF

27. Body mass index and cardiorenal outcomes in the EMPEROR‐Preserved trial: Principal findings and meta‐analysis with the DELIVER trial

Author

Sattar, Naveed, primary, Butler, Javed, additional, Lee, Matthew M.Y., additional, Harrington, Josephine, additional, Sharma, Abhinav, additional, Zannad, Faiez, additional, Filippatos, Gerasimos, additional, Verma, Subodh, additional, Januzzi, James L., additional, Ferreira, João Pedro, additional, Pocock, Stuart J., additional, Pfarr, Egon, additional, Ofstad, Anne P., additional, Brueckmann, Martina, additional, Packer, Milton, additional, and Anker, Stefan D., additional

Published
2024
Full Text
View/download PDF

28. Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert Panel

Author

Psotka, Mitchell A., Abraham, William T., Fiuzat, Mona, Filippatos, Gerasimos, Lindenfeld, JoAnn, Ahmad, Tariq, Felker, G. Michael, Jacob, Richard, Kitzman, Dalane W., Leifer, Eric S., Lewis, Eldrin F., Mentz, Robert J., Nkulikiyinka, Richard, Ni, Wei, Schaber, Daniel E., Sharma, Abhinav, Solomon, Scott D., Stockbridge, Norman, Teerlink, John R., Unger, Ellis F., Whellan, David J., Wittes, Janet, Anker, Stefan D., and O’Connor, Christopher M.

Published
2022
Full Text
View/download PDF

30. Medication dosing for heart failure with reduced ejection fraction — opportunities and challenges

Author

Marti, Catherine N, Fonarow, Gregg C, Anker, Stefan D, Yancy, Clyde, Vaduganathan, Muthiah, Greene, Stephen J, Ahmed, Ali, Januzzi, James L, Gheorghiade, Mihai, Filippatos, Gerasimos, and Butler, Javed

Subjects
Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Clinical Trials and Supportive Activities, Clinical Research, Cardiovascular, Cardiovascular Agents, Dose-Response Relationship, Drug, Heart Failure, Humans, Patient Selection, Practice Guidelines as Topic, Stroke Volume, Heart failure, Reduced ejection fraction, Medications, Doses, Outcomes, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

Multiple drug classes have shown incremental benefits in heart failure with reduced ejection fraction. Most of these trials were designed to achieve specific doses of the investigational agent. Clinical practice guidelines recommend using the same target dosing of therapies, as tolerated. However, with the increasing number of available therapies, clinicians face the challenge of simultaneously using several drugs, achieving target doses, and managing side effects that are often overlapping. Blood pressure, renal function, hyperkalaemia, and other factors may impede achieving target doses of all medications, leaving clinicians with dilemmas as to how to sequence and dose these various classes of drugs. The guideline-directed eligibility for certain drugs and devices requires stability on maximally tolerated doses of background therapies. However, significant variability exists in dosing achieved in clinical practice. We discuss the existing background data regarding the doses of heart failure medications in clinical trials and in practice, and provide recommendations on how to navigate this complex therapeutic decision-making.

Published
2019

34. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis

Author

Sarafidis, Pantelis, Agarwal, Rajiv, Pitt, Bertram, Wanner, Christoph, Filippatos, Gerasimos, Boletis, John, Tuttle, Katherine R., Ruilope, Luis M., Rossing, Peter, Toto, Robert, Anker, Stefan D., Liu, Zhi-Hong, Joseph, Amer, Ahlers, Christiane, Brinker, Meike, Lawatscheck, Robert, Bakris, George, Aizenberg, Diego, Bartolacci, Inés, Besada, Diego, Bittar, Julio, Chahin, Mariano, Elbert, Alicia, Gelersztein, Elizabeth, Liberman, Alberto, Maffei, Laura, Manghi, Federico Pérez, Sanabria, Hugo, Vallejos, Augusto, Viñes, Gloria, Wassermann, Alfredo, Abhayaratna, Walter, Acharya, Shamasunder, Ekinci, Elif, Lee, Darren, MacIsaac, Richard, Mah, Peak Mann, Nelson, Craig, Packham, David, Pape, Alexia, Roger, Simon, Stephenson, Hugo, Suranyi, Michael, Wittert, Gary, Vale, Elizabeth, Colman, Peter, Colquhoun, David, Ellis, Chris, Joshua, Kim, Pedagogos, Eugenia, Regal, Paul, Topliss, Duncan, Vandeleur, James, Verjans, Johan, Wittert, Gary, Wynne, Katie-Jane, Clodi, Martin, Ebenbichler, Christoph, Fliesser-Görzer, Evelyn, Hanusch, Ursula, Krebs, Michael, Lhotta, Karl, Ludvik, Bernhard, Mayer, Gert, Neudorfer, Peter, Paulweber, Bernhard, Prager, Rudolf, Preiß, Wolfgang, Prischl, Friedrich, Schernthaner, Gerit-Holger, Sourij, Harald, Wiesholzer, Martin, Drexel, Heinz, Oberbauer, Rainer, Schönherr, Hans-Robert, Doubel, Peter, Engelen, Wendy, Gillard, Pieter, Hougardy, Jean-Michel, Krzesinski, Jean-Marie, Maes, Bart, Speeckaert, Marijn, Stas, Koen, van Gaal, Luc, Vanbelleghem, Hilde, Duyck, Francis, Scheen, André, Antunes, Daniela, Botelho, Roberto, Brito, Claudia, Canani, Luis, Canziani, Maria Eugenia, Cerqueira, Maria, de Paula, Rogerio, Eliaschewitz, Freddy, Figueiredo, Carlos Eduardo, Forti, Adriana, Hissa, Miguel, Leite, Emerson Lima Maurilo, Jr, Noronha, Irene, Paolino, Bruno, Paschoalin, Nathalia, Paschoalin, Raphael, Filho, Roberto Pecoits, Pereira, Marcio, Portes, Evandro, Precoma, Dalton, Rea, Rosangela, Riella, Miguel, Salles, Joao Eduardo, Vasconcellos, Eduardo, Vencio, Sergio, Bacci, Marcelo, Maia, Lilia, Villacorta, Aline, Apostolova, Emiliya, Boshnyashka, Radostina, Farah, Ghassan, Georgiev, Dimitar, Gushterova, Valentina, Klyuchkova, Neli, Lucheva, Mariya, Manova, Petya, Minkova, Dotska, Nonchev, Boyan, Pichmanova, Mariyana, Prakova, Zhulieta, Rangelov, Rangel, Rashkov, Rosen, Stanchev, Pavel, Stoyanovska-Elencheva, Bilyana, Tagarev, Zhivko, Temelkova-Kurktschieva, Theodora, Vasileva, Svetla, Yoncheva-Mihaylova, Mariana, Marinchev, Angel, Miteva, Mariya, Barre, Paul, Carlson, Brian, Conway, James, Cournoyer, Serge, Dumas, Richard, Fikry, Sameh, Goluch, Richard, Hamet, Pavel, Hart, Randolph, Henein, Sam, Liutkus, Joanne, Madore, Francois, Martinho, Valdemar, Mazza, Giuseppe, McFarlane, Philip, Keefe, Dennis O′, Peterson, Sean, Schwartz, Daniel, Shu, Daniel, Steele, Andrew, Tellier, Guy, Tennankore, Karthik, Tobe, Sheldon, Tsoukas, George, Tytus, Richard, Vitou, Louise, Walsh, Michael, Weisnagel, Stanley, Wilderman, Igor, Yale, Jean-Francois, El Boreky, Fadia, Kelly, Alan, Leiter, Lawrence, Teitelbaum, Ivor, Cobos, Jorge, Godoy, Juan, González, Fernando, Lobos, Sergio, Palma, Juan Carlos, Prieto Dominguez, Juan Carlos, Reyes, Eliana, Romero, Carmen, Saavedra, Victor, Vega, Mario, Medina, Marcelo, Varleta, Paola, Bu, Ruifang, Cai, Hanqing, Chen, Nan, Chen, Qinkai, Chen, Dejun, Cheng, Jinluo, Dong, Youping, Dong, Junwu, Guan, Tianjun, Hao, Chuanming, Huang, Wen, Jiang, Fangfang, Lei, Minxiang, Li, Ling, Li, Zhonghe, Li, Xuemei, Li, Jingmei, Li, Yan, Liang, Xinling, Liang, Bo, Liu, Fang, Liu, Yinghong, Liu, Yuantao, Liu, Zhihong, Long, Gang, Lu, Guoyuan, Lu, Weiping, Lu, Yibing, Luo, Ping, Ma, Jianhua, Mo, Zhaohui, Niu, Jianying, Peng, Ai, Shen, Jiansong, Shen, Feixia, Shi, Bingyin, Su, Qing, Sun, Zhuxing, Tang, Shuifu, Tong, Nanwei, Wang, Hao, Wang, Xinjun, Wang, Guixia, Wang, Jianqin, Wang, Yangang, Wang, Li, Wei, Jiali, Wu, Tianfeng, Wu, Chaoqing, Xing, Changying, Xiong, Fei, Xu, Xudong, Xu, Ning, Yan, Tiekun, Yang, Jinkui, Yin, Aiping, Zeng, Longyi, Zhang, Hao, Zhang, Yanlin, Zhang, Ying, Zhao, Wenjing, Zhao, Zhiquan, Zheng, Hongguang, Zhong, Ling, Zhu, Dalong, Zhuang, Yongze, Du, Yuming, Fang, Yi, Guo, Weiying, Jiang, Sheng, Kuang, Jian, Li, Dongmei, Li, Hongmei, Li, Yinan, Li, Yuxiu, Liu, Jian, Liu, Yu, Miao, Heng, Peng, Wen, Wang, Lihua, Xu, Mingtong, Zhong, Liyong, Zhu, Jun, Arango, Clara, Barrera, Sandra, López, Nelly Beltrán, Benitez, Diego, Blanco, Guillermo, Cadena, Andrés, Coronel, Julian, Cure, Carlos, Durán, Carlos, González, Alexander, Guzmán, Gustavo, Hernández, Eric, Ibarra, Jaime, Jaramillo, Carlos, Jaramillo, Nicolás, Kattah, William, Molina, Dora, Sánchez, Gregorio, Terront, Mónica, Trujillo, Freddy, Urina, Miguel, Vargas, Ruben, Villegas, Iván, Yupanqui, Hernán, Arcos, Edgar, Aroca, Gustavo, Barreto, Germán, Bermudez, Andres, Botero, Rodrigo, Cárdenas, Tatiana, Figueroa, Wilmer, Jaramillo, Mónica, Liévano, Manuel, López, Mónica, Molina, Dora, Rosero, Ricardo, Trillos, Pedro, Dino Alferi, Brada, Michal, Brezina, Jiri, Bucek, Petr, Edelsberger, Tomas, Gulakova, Drahomira, Zapletalova, Jitka Hasalova, Hola, Olga, Hornova, Lucie, Houdova, Jana, Hrmova, Helena, Karasek, David, Kopecka, Sarka, Kovar, Richard, Krcova, Eva, Kuchar, Jiri, Kutejova, Vlasta, Lubanda, Hana, Matyasek, Ivo, Mokrejsova, Magdalena, Okenka, Libor, Prazny, Martin, Pumprla, Jiri, Tomanek, Pavel, Andersen, Ulla, Andries, Alin, Bech, Jesper, Faber, Jens, Gislason, Gunnar, Hangaard, Jørgen, Pacyk, Grzegorz Jaroslaw, Juhl, Claus, Krarup, Thure, Lindhardt, Morten, Madsbad, Sten, Nielsen, Joan, Pedersen-Bjergaard, Ulrik, Poulsen, Per, Rasmussen, Ole, Rossing, Peter, Schousboe, Karoline, Gram, Jeppe, Lauridsen, Thomas, Pedersen, Erling, Thorsteinsson, Birger, Flöjt, Päivi, Honkasalo, Mikko, Honkasalo, Mikko, Humaloja, Kari, Kananen, Kristiina, Kantola, Ilkka, Koistinen, Arvo, Korsoff, Pirkko, Lahtela, Jorma, Nieminen, Sakari, Nieminen, Tuomo, Sadeharju, Karita, Strand, Jorma, Sulosaari, Sakari, Cariou, Bertrand, Chantrel, François, Clavel, Sylvaine, Combe, Christian, Fauvel, Jean-Pierre, Gallouj, Karim, Gouet, Didier, Guerci, Bruno, Guerrot, Dominique, Hourmant, Maryvonne, Klein, Alexandre, Mariat, Christophe, Marre, Michel, Mesbah, Rafik, Le Meur, Yannick, Monier, Arnaud, Moranne, Olivier, Roussel, Ronan, Serusclat, Pierre, Vendrely, Benoit, Verges, Bruno, Zaoui, Philippe, Axthelm, Christoph, Bergmann, Andreas, Birkenfeld, Andreas L., Braun, Hermann, Busch, Klaus, Contzen, Christel, Degenhardt, Stefan, Derwahl, Karl, Giebel, Thomas, Hagenow, Andreas, Haller, Hermann, Hasslacher, Christoph, Horacek, Thomas, Jungmair, Wolfgang, Kloos, Christof, Koch, Thorsten, Krüger, Thilo, Mühlfeld, Anja, Müller, Joachim, Pfützner, Andreas, Pistrosch, Frank, Rinke, Andrea, Rose, Ludger, Rump, Lars, Schettler, Volker, Schiefke, Ingolf, Schlichthaar, Heike, Schröppel, Bernd, Schöll, Norbert, Schubert, Kristin, Schürholz, Thomas, Sigal, Helena, Stemler, Lutz, Strack, Georg, Täschner, Heidrun, Toursarkissian, Nicole, Tschöpe, Diethelm, Ulmer, Achim, van der Giet, Markus, Wanner, Christoph, Winkelmann, Bernhard R., Boletis, Ioannis, Dimitriadis, George, Hatziagelaki, Erifili, Iatrou, Christos, Ioannidis, Ioannis, Kounadi, Theodora, Makriniotou, Ioanna, Papadopoulou, Dorothea, Papagianni, Aikaterini, Passadakis, Ploumis, Piaditis, George, Stefanidis, Ioannis, Tai Pang Ip, Lee, Paul, Andrea Luk, On Yan, Ma, Ronald, Chow, Wing Sun, Wang, Angela, Yeung, Vincent, Bajcsi, Dora, Danos, Peter, Harcsa, Eleonora, Kalina, Akos, Kazup, Szilvia, Keltai, Katalin, Kirschner, Robert, Kiss, Julianna, Kovacs, Laszlo, Lamboy, Beata, Literati-Nagy, Botond, Mileder, Margit, Nagy, Laszlo, Noori, Ebrahim, Nyirati, Gabor, Petro, Gizella, Schneider, Karoly, Simon, Judit, Szocs, Albert, Vasas, Szilard, Wudi, Krisztina, Zilahi, Zsolt, Zsom, Marianna, Eustace, Joe, Holian, John, Reddan, Donal, Meara, Yvonne O′, Abramof Ness, Rosane, Adawi, Faiad, Armaly, Zaher, Atar, Shaul, Bashkin, Amir, Ben Chetrit, Sydney, Yanay, Noa Berar, Chernin, Gil, Darawsha, Mahmud, Efrati, Shai, Elias, Mazen, Farber, Evgeny, Glandt, Mariela, Grossman, Ehud, Halabi, Majdi, Harman-Boehm, Ilana, Khazim, Khaled, Liberty, Idit, Minuchin, Oscar, Mosenzon, Ofri, Nakhoul, Farid, Nimer, Assy, Schwartz, Doron, Wainstein, Julio, Yagil, Yoram, Zukermann, Robert, Avogaro, Angelo, Battaglia, Giovanni Giorgio, Bevilacqua, Maurizio Tiziano, Bonora, Enzo, Bossi, Carlo Antonio, Calabrò, Paolo, Cavalot, Franco Luigi, Cimino, Roberto, Cozzolino, Mario Gennaro, David, Salvatore, Emdin, Michele, Fiaccadori, Enrico, Fiorina, Paolo, Giorda, Carlo Bruno, Gregorini, Maria Cristina, La Manna, Gaetano, Maggi, Davide Carlo, Manti, Roberta, Meregalli, Giancarla, Pani, Antonello, Parvanova, Aneliy Ilieva, Perico, Norberto, Piatti, PierMarco, Pisani, Antonio, Pontiroli, Antonio Ettore, Ponzani, Paola, Santorelli, Gennaro, Santoro, Domenico, Scanziani, Renzo, Teatini, Ugo, Tonolo, Giancarlo, Trevisan, Roberto, Veronelli, Anna Maria, Viviani, Giorgio Luciano, Araki, Hideo, Bando, Yukihiro, Ebisui, Osamu, Fujita, Naruhiro, Fukasawa, Hirotaka, Furuya, Ryuichi, Hamamoto, Yoshiyuki, Hamasaki, Akihiro, Hasegawa, Kotaro, Hatazaki, Masahiro, Hayashi, Terumasa, Higashi, Takayuki, Hirohata, Yoshihide, Horinouchi, Shuji, Hoshi, Ayumu, Imoto, Hirofumi, Inagaki, Akemi, Inagaki, Masayuki, Inaguma, Daijo, Inoue, Toshihiko, Ishii, Masao, Ishiko, Tamayo, Isono, Motohide, Jinnouchi, Hideaki, Kanai, Hidetoshi, Kanda, Daisuke, Kanehara, Hideo, Kashima, Masayuki, Kataoka, Yuko, Katayama, Shigehiro, Kato, Kiyoe, Katsuki, Takeshi, Kawamitsu, Katsunori, Kawasaki, Satsuki, Kikuchi, Fumi, Kikuchi, Hidetoshi, Kishimoto, Rui, Kobayashi, Kunihisa, Koide, Junko, Komi, Rieko, Kubota, Miyuki, Kuriya, Genpei, Kurose, Takeshi, Kusano, Yoshiro, Hajime, Maeda, Matsubayashi, Sunao, Matsumoto, Kazunari, Matsumura, Naoya, Matsuo, Yasuto, Matsuoka, Naoki, Miyaoka, Hiroaki, Miyata, Satoshi, Morita, Takeshi, Murakami, Isao, Murao, Satoshi, Nakamura, Udai, Nakayama, Mikihiro, Nakazawa, Jun, Nohara, Sakae, Nomiyama, Takashi, Noritake, Masayuki, Oda, Yoshiaki, Ogiwara, Takayuki, Ohashi, Hiroshi, Okamoto, Hideki, Okino, Shinichi, Osonoi, Takeshi, Sasaki, Nobuhiro, Sayo, Yoshitaka, Sekigami, Taiji, Shibasaki, Taro, Shibata, Hirotaka, Shimoyama, Tatsushi, Shinoda, Junji, Sobajima, Hiroshi, Sugitatsu, Kazuya, Sugiura, Toshiyuki, Sugiyama, Toru, Suzuki, Daisuke, Suzuki, Hiroyuki, Suzuki, Masaaki, Takeda, Asami, Tanaka, Asami, Tanaka, Seiichi, Tsunematsu, Izumi, Ueda, Yasuo, Uekihara, Soichi, Ujihara, Makoto, Yajima, Ken, Yamada, Daishiro, Yamada, Masayo, Yamagata, Kazuo, Yamakawa, Ken, Yamakawa, Fumiko, Yamasaki, Yoshimitsu, Yambe, Yuko, Yanagida, Taihei, Yanai, Hidekatsu, Yanase, Toshihiko, Yasuda, Tetsuyuki, Kriauciuniene, Dovile, Lasiene, Jurate, Navickas, Antanas, Radzeviciene, Lina, Urbanaviciene, Egle, Urbonas, Gediminas, Velaviciene, Audrone, Abd Ghani, Rohana, Aziz, Nor Azizah, Lee, Li Yuan, Loh, Chek Loong, Ali, Norhaliza Mohd, Noor, Nurain Mohd, Fatnoon Nik Ahmad, Nik Nur, Ratnasingam, Jeyakantha, Halimi Bin Wan Hasan, Wan Hasnul, Izani Wan Mohamed, Wan Mohd, Khir, Rizmy Najme, Mohamad, Masni, Alexander Tan, Tong Boon, Avila Pardo, Sandro, Adrian, Miriam Bastidas, Wong, Alfredo Chew, Escobedo de la Peña, Jorge, Salmón, Guillermo Fanghänel, Gálvez, Guillermo González, Ochoa, Ramiro Gutiérrez, Santana, Saúl Irizar, Rovalo, Magdalena Madero, Machado, Gustavo Méndez, Ruiz, Luis Nevarez, Ibarra, Denisse Ramos, López, Gabriel Ramos, Reyna, Leobardo Sauque, Ortiz, Gustavo Solache, Ortiz, Rafael Valdez, Mesa, Juan Villagordoa, Salazar, Melchor Alpizar, Hernández, Pedro García, González, José, Soto, José Lazcano, Mendoza, Arturo Saldaña, Santana, Sergio Irizar, Vilchis, Elvira González, Bakker, R.C., Barendregt, J.N.M., Boonstra, A.H., Bos, Willem, Brouwer, C.B., Buren, M. van, Gansevoort, Ron, Kooy, Adriaan, Krekels, Marielle, Leendert, Ruud J.M. van, Lieverse, Louis A.G., Luik, P.T., Penne, E. Lars, Gregoor, Peter Smak, Vogt, Liffert, Born, Bert-Jan van den, John Baker, Crawford, Veronica, Cutfield, Rick, Dunn, Peter, Krebs, Jeremy, Nirmalaraj, Kingsley, Scott, Russell, Smuts, Nine, Titchener, Janet, Eriksen, Erik, Finnes, Trine, Høivik, Hans, Karlsson, Thomas, Munk, Peter Scott, Radtke, Maria, Risberg, Knut, Rocke, Jan, Solnør, Leidulv, Stenehjem, Aud-Eldrid, Tafjord, Anne-Beathe, Asprusten, Emil, Hagemeier, Robert, Høye, Kjetil, Selsås, Hilde, Thorup, Frode, Wium, Cecilie, Pamugas, Glenda, Panelo, Araceli, Perez, Ronald, Tanque, Maribel, Tirador, Louie, Villa, Michael, Bautista, Albert, Catindig, Elizabeth, Manalo, Carlo, Mirasol, Roberto, Butrymowicz, Patrycja, Ciechanowski, Kazimierz, Cieslik, Grazyna, Franek, Edward, Gumprecht, Janusz, Hoffmann, Michal, Krzykowska, Jolanta, Kurnatowska, Ilona, Landa, Katarzyna, Madrzejewski, Adam, Madziarska, Katarzyna, Mazur, Stanislaw, Napora, Piotr, Nowicki, Michal, Ocicka-Kozakiewicz, Anna, Rewerska, Barbara, Rusicka, Teresa, Ruxer, Jan, Skokowska, Ewa, Stankiewicz, Andrzej, Stompor, Tomasz, Tiuryn-Petrulewicz, Agnieszka, Wasilewska, Katarzyna, Wierusz-Wysocka, Bogna, Wnetrzak-Michalska, Renata, Jedynasty, Krystyna, Anand, Izabela Sein, Almeida, Edgar, Ballesteros, Rosa, Barreto, Carlos, Beirao, Idalina, Birne, Rita, Esteves, Cesar, Guia, Jose, Heitor, Susana, Marques, Olinda, Melo, Pedro, Nolasco, Fernando, Pereira, Amalia, Roque, Cristina, Rosario, Francisco, Silva, Gil, Silva, Ana, Teixeira e Costa, Fernando, Lobos, Ana Vila, Alves, Ana Rita, Brandao, Ilidio, Carvalho, Rui, Coelho, Joao, Lourenco, Ana, Matos, Pedro, Rosario, Vanisa, Neves, Joao Sergio, Cortes-Maisonet, Gregorio, Roman-Miranda, Amaury, Brito-Peguero, Yudit, Colon-Vega, Gildred, Albota, Adrian, Bala, Cornelia, Barbonta, Hortensia, Caceaune, Elena, Catrinoui, Doina, Constantin, Ciprian, Dumitrescu, Adriana, Mindrescu, Nicoleta, Mistode, Cristina, Negrisanu, Gabriela, Onaca, Adriana, Paveliu, Silvia, Pintilei, Ella, Pop, Lavinia, Popa, Amorin, Popescu, Alexandrina, Radulian, Gabriela, Szilagyi, Iosif, Turcu, Liana, Vacaru, Georgeta, Vlad, Adrian, Filimon, Adriana, Veresiu, Ioan, Antsiferov, Mikhail, Arkhipov, Mikhail, Babkin, Andrey, Barbarash, Olga, Baranov, Vitaliy, Chernyavskaya, Elena, Demko, Arkadiy, Dreval, Alexander, Edin, Anton, Ermakova, Polina, Fadeev, Valentin, Galyavich, Albert, Gaysina, Leyla, Gordeev, Ivan, Ipatko, Irina, Kalashnikova, Marina, Khalimov, Yuriy, Klimontov, Vadim, Kobalava, Zhanna, Kosmacheva, Elena, Koziolova, Natalya, Sergey Levashov, Lyudmila Kvitkova, Libis, Roman, Marasaev, Vyacheslav, Malykh, Natalia, Martynenko, Vladimir, Malyutina, Sofya, Merai, Imad, Mkrtumyan, Ashot, Nechaeva, Galina, Petunina, Nina, Palyutin, Shamil, Pimenov, Leonid, Rechkova, Elena, Rodionova, Tatyana, Rymar, Oksana, Sardinov, Ruslan, Semenova, Olga, Sherenkov, Alexander, Solovev, Oleg, Smolyarchuk, Elena, Strongin, Leonid, Ukhanova, Olga, Verlan, Nadezhda, Vorokhobina, Natalya, Yakhontov, Davyd, Yakushin, Sergey, Zakharova, Elena, Zalevskaya, Alsu, Zanozina, Olga, Zhdanova, Elena, Zhukova, Larisa, Zykova, Tatyana, Argunova, Yulia, Nikolaev, Konstantin, Villevalde, Svetlana, Fang Sum, Chee, Suhail, Sufi Muhummad, San Tan, Ru, Vathsala, Anantharaman, Wong, Edmund, Bee, Yong Mong, Babikova, Jana, Buganova, Ingrid, Dzupina, Andrej, Ochodnicka, Zuzana, Sosovec, Dalibor, Spodniakova, Denisa, Minarik, Peter, Fayzal Ahmed, Amod, Aslam, Bhana, Sindeep, Distiller, Larry, Jansen van Rensburg, Dirkie, Joshi, Mukesh, Joshi, Shaifali, Lakha, Deepak, Mitha, Essack, Podgorski, Gracjan, Ranjith, Naresh, Rayner, Brian, Rheeder, Paul, Sarvan, Mohamed, Seeber, Mary, Siebert, Heidi, Tayob, Mohammed, Trokis, Julien, Urbach, Dorothea, van Zyl, Louis, Jansen van Rensburg, Dirkie, Bum-Soon Choi, Choi, Moon Gi, Chung, ChoonHee, Hwang, YouCheol, Kim, ChongHwa, Kim, InJoo, Kim, JaeHyeon, Kim, SinGon, Kim, SungGyun, Kim, Tae Hee, Lee, WooJe, Lee, ByungWan, Lee, Kang Wook, Oh, Kook-Hwan, Oh, Ji Eun, Oh, Yun Kyu, Oh, Dong-Jin, Park, Junbeom, Shin, Seok Joon, Sung, Su-Ah, Yu, Jae Myung, Chung, HyeSoo, Huh, Ji Hye, Kang, JunGoo, Kim, ChulSik, Kim, HyeSoon, Kim, NamHoon, Lim, Soo, Cho, Young Min, Park, Cheol Young, Agraz, Irene, Ampudia, Francisco Javier, Bouarich, Hanane, Calero, Francesca, Castro, Cristina, Guldris, Secundino Cigarrán, Garrit, Josep Cruzado, de Álvaro, Fernando, Galcerán, Josep, Albarrán, Olga González, Jaras, Julio Hernández, Ibernón, Meritxell, Deben, Francisco Martínez, Ma, Esteban, Dolores Martínez, Pascual Izuel, José María, Martins, Judith, Mediavilla, Juan, Michán, Alfredo, Santos, Julio Pascual, Poch, Esteban, Rusillo, Manuel Polaina, Juan, Carlos Sánchez, Olmo, Rafael Santamaría, Segura de la Morena, José Julián, Soto, Alfonso, Troya, Maribel, Castro, Fernando Cereto, Fernández, Pablo Gómez, Sánchez, Laura Fuentes, Moya, Mercedes González, Marrero, Domingo Hernández, Maroto, Gonzalo Piedrola, Redón, Josep, Seron, Daniel, Bruchfeld, Annette, Curiac, Dan, Eliasson, Ken, Frank, Malin, Guron, Gregor, Hellberg, Olof, Hellgren, Margareta, Larnefeldt, Hans, Lindholm, Carl-Johan, Löndahl, Magnus, Rein-Hedin, Erik, Soveri, Inga, Spaak, Jonas, Tengmark, Bengt-Olov, Lif-Tiberg, Cornelia, Månflod, Johan, Nguyen, Han, Ackermann, Daniel, Bilz, Stefan, Burnier, Michel, Forster, Christian, Kalbermatter, Stefan, Kistler, Andreas, Pechère-Bertschi, Antoinette, Schultes, Bernd, Laimer, Markus, Rudofsky, Gottfried, Strey, Christopher, Wuerzner, Gregoire, Chiz-Tzung Chang, Hung, Cheng-Chieh, Jiang, Ju-Ying, Lee, Chien-Te, Lin, Shuei-Liong, Tarng, Der-Cherng, Tu, Shih-Te, Wu, Mai-Szu, Wu, Ming-Ju, Chuang, Lee-Ming, Deerochanawong, Chaicharn, Kitiyakara, Chagriya, Ophascharoensuk, Vuddhidej, Pongchaiyakul, Chatlert, Satirapoj, Bancha, Kosachunhanan, Natapong, Sritara, Piyamitr, Eren, Necmi, Gul, Ibrahim, Gulel, Okan, Kocyigit, Ismail, Kumbasar, Abdulbaki, Sahin, Idris, Sari, Ramazan, Sayin, Burak, Tavli, Talat, Ustundag, Sedat, Yenicerioglu, Yavuz, Badak, Ozer, Cayli, Murat, Oguz, Aytekin, Ozdogan, Oner, Sari, Ibrahim, Temizhan, Ahmet, Tigen, Mustafa, Turk, Ugur, Yilmaz, Huseyin, Yilmaz, Mehmet, Bondarets, Iryna, Botsyurko, Volodymyr, Chernikova, Viktoriia, Donets, Oleksandra, Fushtey, Ivan, Grachova, Mariia, Isayeva, Anna, Kogut, Dmytro, Komisarenko, Julia, Kravchun, Nonna, Malyar, Kateryna, Mankovsky, Borys, Martynyuk, Liliya, Maslyanko, Vitaliy, Myshanych, Halyna, Pererva, Larysa, Pertseva, Nataliia, Serhiyenko, Oleksandr, Smirnov, Ivan, Sokolova, Liubov, Stryzhak, Vasyl, Vlasenko, Maryna, Isayeva, Ganna, Larin, Oleksandr, Ahmad AbouSaleh, Barratt, Jonathan, Dang, Cuong, Kahal, Hassan, Kirk, Adam, Kilvert, Anne, Kon, Sui Phi, McCafferty, Kieran, Patel, Dipesh, Rice, Sam, Vijayaraman, Arutchelvam, Wong, Yuk-ki, Gibson, Martin, Wahba, Mona, Zaidi, Reza, Bilous, Rudy, Johnson, Andrew, Kalathil, Dhanya, Kilvert, Anne, Kyriakidou, Christina, Mathew, Amit, Mukhtar, Rasha, Munsoor, Imrozia, Poterajlo, Anton, Swift, Pauline, Idalia Acosta, Adams, Atoya, Adler, Sharon, Ajani, Dilawar, Ali, Slamat, Alicic, Radica, Al-Karadsheh, Amer, Alla, Sreedhara, Allison, D., Andrawis, Nabil, Arif, Ahmed, Awad, Ahmed, Azizad, Masoud, Bahrami, Michael, Bansal, Shweta, Barag, Steven, Barakzoy, Ahmad, Barney, Mark, Barzilay, Joshua, Bashir, Khalid, Bautista, Jose, Beddhu, Srinivasan, Belo, Diogo, Benjamin, Sabrina, Berenji, Ramin, Bhargava, Anuj, Birriel, Jose, Brietzke, Stephen, Brosius, Frank, Brusco, Osvaldo, Burgner, Anna, Busch, Robert, Canadas, Rafael, Caramori, Maria, Cardona, Jose, Case, Christopher, Cruz, Humberto, Dandillaya, Ramprasad, Dawoud, Dalia, Din, Zia, Dixon, Bradley, Doshi, Ankur, Drakakis, James, El Shahawy, Mahfouz, El-Meanawy, Ashraf, El-Shahawy, Mohammed, Evans, John, Fadda, George, Farooq, Umar, Fernando, Roland, Fink, Raymond, First, Brian, Fitz-Patrick, David, Flack, John, Fluck, Patrick, Fogelfeld, Leon, Fonseca, Vivian, Frias, Juan, Galphin, Claude, Garcia-Mayol, Luis, Goldstein, Gary, Gonzalez, Edgar, Gonzalez-Abreu, Francisco, Gore, Ashwini, Grant, David, Habwe, Violet, Hamilton, Maxine, Hammoud, Jamal, Handelsman, Stuart, Hartman, Israel, Heigerick, Glenn, Henry, Andrew, Hernandez, German, Hernandez-Cassis, Carlos, Herrera, Carlos, Hertel, Joachim, Huang, Wenyu, Iglesias, Rogelio, Iranmanesh, Ali, Jackson, Timothy, Jain, Mahendra, Jamerson, Kenneth, Johnson, Karen, Judd, Eric, Kaplan, Joshua, Kayali, Zeid, Khan, Bobby, Khan, Muhammad, Kharait, Sourabh, Kirkman, M. Sue, Kopyt, Nelson, Kotzker, Wayne, Kovesdy, Csaba, Kreit, Camil, Krishna, Arvind, Kronfli, Saeed, Lee, Keung, LeJeune, Derek, Lemus, Brenda, Leon-Forero, Carlos, Linfert, Douglas, Lora, Henry, Lurie, Alexander, Maddukuri, Geetha, Magno, Alexander, Maletz, Louis, Mandayam, Sreedhar, Markell, Mariana, Mayfield, Ronald, Mbogua, Caroline, McMullen, Dierdre, Meisner, Carl, Minton, Stephen, Mocherla, Bharat, Mohandas, Rajesh, Montero, Manuel, Moustafa, Moustafa, Nadkarni, Salil, Nakhle, Samer, Navarro, Jesus, Neyra, Nilda, Nica, Romanita, Nicol, Philip, Norwood, Paul, Numrungroad, Visal, Donovan, Richard O′, Odugbesan, A., Paoli-Bruno, Jorge, Parikh, Samir, Patel, Rakesh, Peixoto, Aldo, Pergola, Pablo, Perlman, Alan, Pettis, Karlton, Pisoni, Roberto, Ponduchi, Mirela, Posada, Jorge, Prabhakar, Sharma, Radhakrishnan, Jai, Rahman, Mahboob, Raina, Rupesh, Rastogi, Anjay, Reisin, Efrain, Rendell, Marc, Robertson, David, Rocco, Michael, Romeu, Hugo, Rosas, Sylvia, Rosenfeld, Jack, Ross, Dennis, Rothman, Jeffrey, Rudolph, Lance, Ruhullah, Yusuf, Ruoff, Gary, Ryu, Jeffrey, Sahani, Mandeep, Sam, Ramin, Samuels, Garfield, Sanchez, William, Santos, Vladimir, Satko, Scott, Saxena, Sanjeev, Scott, David, Seco, Gilberto, Seek, Melvin, Serota, Harvey, Shafi, Tariq, Shahid, Nauman, Shanik, Michael, Sharma, Santosh, Sinha, Arjun, Smelser, James, Smith, Mark, Soe, Kyaw, Solomon, Richard, Soroka, Eugene, Soufer, Joseph, Spinowitz, Bruce, Spry, Leslie, Suarez, Rosa, Subramanian, Bala, Szerlip, Harold, Tamirisa, Aparna, Thomson, Stephen, Tran, Tuan-Huy, Treger, Richard, Trullenque, Gretel, Turk, Thomas, Umpierrez, Guillermo, Urbach, Daniel, Valdes, Martin, Valika, Shujauddin, Vega, Damaris, Weissman, Peter, Whaley-Connell, Adam, Winston, Jonathan, Wise, Jonathan, Wynne, Alan, Zeig, Steven, Abdel-Rahman, Emaad, Abreu, Edel, Awad, Alaa, Bahri, Nader, Bertsch, John, Bleich, David, Bornfreund, Jonathan, Brar, Harjeet, Brian, Susan, Brinson, Cynthia, Bruschetta, Humberto, Carpio, Jose, Cohen, Steven, Cosby, John, Dhanireddy, Soni, Diaz, Jorge, Dunn, Fredrick, Eppanapally, Sabitha, Fayad, Joseph, Goel, Archana, Govindaraju, Kanakadurga, Halpern, Stephen, Jones, Audrey, Kaye, William, Knight, Herbert, Koch, Stanley, Kohli, Nandini, Lastra, Guido, Lerman, Sam, Loredo, Jorge, Lovre, Dragana, Mandviwala, Mustafa, Martin, Earl, Meyer, Jill, Murray, John, Oliver, David, Oparil, Suzanne, Penabad, Jesus, Pereira, Isabel, Popeil, Larry, Quesada, Gonzalo, Ramanathan, Kodangudi, Ramos-Gonez, Luis, Rastegar, Mandana, Rastogi, Padmashri, Rondon, Juan, Roy-Chaudhury, Prabir, Smith, David, Williamson, Don, Womack, Catherine, Yamout, Hala, Yuryev, Michael, Chu, Phuong, Van Hoang, Lam, Khanh, Tran, Phi Nga, Nguyen Thi, Son, Pham Nguyen, Tran, Lan Phuong, Le, Thuy Khuong, Nguyen, Boi Ngoc, Nguyen, Thao, Nui, Nguyen Minh, Nam, Tran Quang, and Tran, Kim Chi

Published
2023
Full Text
View/download PDF

35. A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research

Author

Brown, Cameron, Mantzaris, Michael, Nicolaou, Elpiniki, Karanasiou, Georgia, Papageorgiou, Elisavet, Curigliano, Giuseppe, Cardinale, Daniela, Filippatos, Gerasimos, Memos, Nikolaos, Naka, Katerina K., Papakostantinou, Andri, Vogazianos, Paris, Ioulianou, Erietta, Shammas, Christos, Constantinidou, Anastasia, Tozzi, Federica, Fotiadis, Dimitrios I., and Antoniades, Athos

Published
2022
Full Text
View/download PDF

36. Epidemiology and risk factors for hyperkalaemia in heart failure.

Author

Grobbee, Diederick E., Filippatos, Gerasimos, Desai, Nihar R., Coats, Andrew J. S., Pinto, Fausto, Rosano, Giuseppe M. C., Cleland, John G. F., Kammerer, Jennifer, and de Arellano, Antonio Ramirez

Subjects
MAJOR adverse cardiovascular events, DISEASE risk factors, HEART failure patients, CHRONIC kidney failure, CLINICAL epidemiology, HEART failure
Abstract

Patients with heart failure (HF), particularly those with impaired renal function receiving renin–angiotensin–aldosterone system inhibitors (RAASis), are at risk of hyperkalaemia; when hyperkalaemia is severe, this can have serious clinical consequences. The incidence, prevalence, and risk factors for hyperkalaemia reported in randomized trials of RAASis may not reflect clinical practice due to exclusion of patients with elevated serum potassium (sK+) or severe renal impairment: information on patients managed in routine clinical care is important to understanding the actual burden of hyperkalaemia. This paper reviews the available clinical epidemiology data on hyperkalaemia in HF and considers areas requiring further research. Observational studies published since 2017 that focused on hyperkalaemia, included patients with HF, and had ≥1000 participants were considered. Hyperkalaemia occurrence in HF varied widely from 7% to 39% depending on the setting, HF severity, follow‐up length, and concomitant medications. Rates were lowest in patients with newly diagnosed HF and highest in patients with greater disease severity; comorbidities, such as chronic kidney disease and diabetes, and RAASi use, reflected commonly identified risk factors for hyperkalaemia in patients with HF. Hyperkalaemia was most often mild; however, from the limited data available, persistence of mild hyperkalaemia was associated with an increased risk of mortality and major adverse cardiovascular events. There were also limited data available on the progression of hyperkalaemia. Recurrence was common, occurring in one‐quarter to two‐fifths of hyperkalaemia cases. Despite HF guidelines recommending close monitoring of sK+, 55–93% of patients did not receive appropriate testing before or after initiation of RAASi or in follow‐up to moderate/severe hyperkalaemia detection. Many of the observational studies were retrospective and from a single country. There is a need for international, prospective, longitudinal, observational studies, such as the CARE‐HK in HF study (NCT04864795), to understand hyperkalaemia's prevalence, incidence, and severity; to identify and characterize cases that persist, progress, and recur; to highlight the importance of sK+ monitoring when using RAASi; and to assess the impact of newer HF therapies and potassium binders in clinical practice. Data from both clinical trials and observational studies with adjustments for confounding variables will be needed to assess the contribution of hyperkalaemia to clinical outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG‐HF.

Author

Voordes, Geert, Davison, Beth, Biegus, Jan, Edwards, Christopher, Damman, Kevin, ter Maaten, Jozine, Mebazaa, Alexandre, Takagi, Koji, Adamo, Marianna, Ambrosy, Andrew P., Arrigo, Mattia, Barros, Marianela, Celutkiene, Jelena, Čerlinskaitė‐Bajorė, Kamilė, Chioncel, Ovidiu, Cohen‐Solal, Alain, Damasceno, Albertino, Deniau, Benjamin, Diaz, Rafael, and Filippatos, Gerasimos

Subjects
ADRENOMEDULLIN, HEART failure, PATIENT readmissions, BRAIN natriuretic factor
Abstract

Aims: Biologically active adrenomedullin (bio‐ADM) is a promising marker of residual congestion. The STRONG‐HF trial showed that high‐intensity care (HIC) of guideline‐directed medical therapy (GDMT) improved congestion and clinical outcomes in heart failure (HF) patients. The association between bio‐ADM, decongestion, outcomes and the effect size of HIC of GDMT remains to be elucidated. Methods and results: We measured plasma bio‐ADM concentrations in 1005 patients within 2 days prior to anticipated discharge (baseline) and 90 days later. Bio‐ADM correlated with most signs of congestion, with the exception of rales. Changes in bio‐ADM were strongly correlated with change in congestion status from baseline to day 90 (gamma −0.24; p = 0.0001). Patients in the highest tertile of baseline bio‐ADM concentrations were at greater risk than patients in the lowest tertile for the primary outcome of 180‐day all‐cause mortality or HF rehospitalization (hazard ratio [HR] 2.14, 95% confidence interval [CI] 1.42–3.22) and 180‐day HF rehospitalization (HR 2.33, 95% CI 1.38–3.94). Areas under the receiver‐operating characteristic curves were 0.5977 (95% CI 0.5561–0.6393), 0.5800 (95% CI 0.5356–0.6243), and 0.6159 (95% CI 0.5711–0.6607) for bio‐ADM, N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) and their combination, respectively, suggesting that both bio‐ADM and NT‐proBNP provided similarly modest discrimination for this outcome. A trend towards better discrimination by combined bio‐ADM and NT‐proBNP than NT‐proBNP alone was found (p = 0.059). HIC improved the primary outcome, irrespective of baseline bio‐ADM concentration (interaction p = 0.37). In contrast to NT‐proBNP, the 90‐day change in bio‐ADM did not differ significantly between HIC and usual care. Conclusions: Bio‐ADM is a marker of congestion and predicts congestion at 3 months after a HF hospitalization. Higher bio‐ADM was modestly associated with a higher risk of death and early hospital readmission and may have added value when combined with NT‐proBNP. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial

Author

Martens, Pieter, Dauw, Jeroen, Verbrugge, Frederik H., Nijst, Petra, Meekers, Evelyne, Augusto, Silvio Nunes, Jr, Ter Maaten, Jozine M., Damman, Kevin, Mebazaa, Alexandre, Filippatos, Gerasimos, Ruschitzka, Frank, Tang, W.H. Wilson, Dupont, Matthias, and Mullens, Wilfried

Published
2023
Full Text
View/download PDF

39. Similar clinical benefits from below‐target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial

Author

Lam, Phillip H, Dooley, Daniel J, Fonarow, Gregg C, Butler, Javed, Bhatt, Deepak L, Filippatos, Gerasimos S, Deedwania, Prakash, Forman, Daniel E, White, Michel, Fletcher, Ross D, Arundel, Cherinne, Blackman, Marc R, Adamopoulos, Chris, Kanonidis, Ioannis E, Aban, Inmaculada B, Patel, Kanan, Aronow, Wilbert S, Allman, Richard M, Anker, Stefan D, Pitt, Bertram, and Ahmed, Ali

Subjects
Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Clinical Sciences, Cardiovascular, Clinical Research, Clinical Trials and Supportive Activities, Heart Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Angiotensin-Converting Enzyme Inhibitors, Canada, Cause of Death, Dose-Response Relationship, Drug, Double-Blind Method, Enalapril, Europe, Follow-Up Studies, Heart Failure, Humans, Stroke Volume, Survival Rate, Treatment Outcome, United States, ACE inhibitors, Target dose, Placebo, Heart failure, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

AimsTo examine associations of below-target and target dose of enalapril, an angiotensin-converting enzyme (ACE) inhibitor, with outcomes in patients with heart failure and reduced ejection fraction (HFrEF) in the Studies of Left Ventricular Dysfunction (SOLVD) Treatment trial.Methods and resultsTwo thousand five hundred and sixty-nine patients with HFrEF (ejection fraction ≤35%) were randomized to below-target (5-10 mg/day) dose placebo (n = 1284) or enalapril (n = 1285). One month post-randomization, blind up-titration to target (20 mg/day) dose was attempted for both study drugs in 2458 patients. Among the 1444 patients who achieved dose up-titration (placebo, n = 748; enalapril, n = 696; mean dose for both groups, 20.0 mg/day), target dose enalapril (vs. target dose placebo) was associated with a 9% absolute lower risk of the combined endpoint of heart failure hospitalization or all-cause mortality [adjusted hazard ratio (HR) 0.70; 95% confidence interval (CI) 0.60-0.81; P < 0.001] during 4 years of follow-up. Among the 1014 patients who could not achieve target dose (placebo, n = 486; enalapril, n = 528; mean dose for both groups, 8.8 mg/day), below-target dose enalapril (vs. below-target dose placebo) was associated with a 12% absolute lower risk of the combined endpoint of heart failure hospitalization or all-cause mortality (adjusted HR 0.68; 95% CI 0.57-0.81; P < 0.001). Among the 1224 patients receiving enalapril, target (vs. below-target) dose had no association with the combined endpoint of heart failure hospitalization or all-cause mortality (adjusted HR 1.04; 95% CI 0.87-1.23; P = 0.695).ConclusionIn patients with HFrEF, the clinical benefits of ACE inhibitors appear to be similar at both below-target and target doses.

Published
2018

41. Validation of the Klinrisk chronic kidney disease progression model in the FIDELITY population

Author

Tangri, Navdeep, primary, Ferguson, Thomas, additional, Leon, Silvia J, additional, Anker, Stefan D, additional, Filippatos, Gerasimos, additional, Pitt, Bertram, additional, Rossing, Peter, additional, Ruilope, Luis M, additional, Farjat, Alfredo E, additional, Farag, Youssef M K, additional, Schloemer, Patrick, additional, Lawatscheck, Robert, additional, Rohwedder, Katja, additional, and Bakris, George L, additional

Published
2024
Full Text
View/download PDF

42. Blood pressure and intensive treatment up‐titration after acute heart failure hospitalization: Insights from the STRONG‐HF trial

Author

Pagnesi, Matteo, primary, Vilamajó, Oscar Alberto Gomez, additional, Meiriño, Alejandro, additional, Dumont, Carlos Alberto, additional, Mebazaa, Alexandre, additional, Davison, Beth, additional, Adamo, Marianna, additional, Arrigo, Mattia, additional, Barros, Marianela, additional, Biegus, Jan, additional, Celutkiene, Jelena, additional, Čerlinskaitė‐Bajorė, Kamilė, additional, Chioncel, Ovidiu, additional, Cohen‐Solal, Alain, additional, Damasceno, Albertino, additional, Diaz, Rafael, additional, Edwards, Christopher, additional, Filippatos, Gerasimos, additional, Gayat, Etienne, additional, Kimmoun, Antoine, additional, Lam, Carolyn S.P., additional, Novosadova, Maria, additional, Pang, Peter S., additional, Ponikowski, Piotr, additional, Saidu, Hadiza, additional, Sliwa, Karen, additional, Takagi, Koji, additional, ter Maaten, Jozine M., additional, Tomasoni, Daniela, additional, Voors, Adriaan A., additional, Cotter, Gad, additional, and Metra, Marco, additional

Published
2024
Full Text
View/download PDF

45. Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Preserved

Author

Rastogi, Tripti, primary, Ferreira, João Pedro, additional, Butler, Javed, additional, Kraus, Bettina Johanna, additional, Mattheus, Michaela, additional, Brueckmann, Martina, additional, Filippatos, Gerasimos, additional, Wanner, Christoph, additional, Pocock, Stuart J., additional, Packer, Milton, additional, Anker, Stefan D., additional, and Zannad, Faiez, additional

Published
2024
Full Text
View/download PDF

46. The effect of sodium–glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta‐analysis

Author

Usman, Muhammad Shariq, primary, Januzzi, James L., additional, Anker, Stefan D., additional, Salman, Ali, additional, Parikh, Puja B., additional, Adamo, Marianno, additional, Filippatos, Gerasimos, additional, Khan, Muhammad Shahzeb, additional, Lala, Anuradha, additional, Verma, Subodh, additional, Metra, Marco, additional, and Butler, Javed, additional

Published
2024
Full Text
View/download PDF

47. Epidemiology, pathophysiology, diagnosis and management of chronic right‐sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC

Author

Adamo, Marianna, primary, Chioncel, Ovidiu, additional, Pagnesi, Matteo, additional, Bayes‐Genis, Antoni, additional, Abdelhamid, Magdy, additional, Anker, Stefan D., additional, Antohi, Elena‐Laura, additional, Badano, Luigi, additional, Ben Gal, Tuvia, additional, Böhm, Michael, additional, Delgado, Victoria, additional, Dreyfus, Julien, additional, Faletra, Francesco F., additional, Farmakis, Dimitrios, additional, Filippatos, Gerasimos, additional, Grapsa, Julia, additional, Gustafsson, Finn, additional, Hausleiter, Jörg, additional, Jaarsma, Tiny, additional, Karam, Nicole, additional, Lund, Lars, additional, Lurz, Philipp, additional, Maisano, Francesco, additional, Moura, Brenda, additional, Mullens, Wilfred, additional, Praz, Fabien, additional, Sannino, Anna, additional, Savarese, Gianluigi, additional, Tocchetti, Carlo Gabriele, additional, van Empel, Vanessa P.M., additional, von Bardeleben, Ralph Stephan, additional, Yilmaz, Mehmet Birhan, additional, Zamorano, José Luis, additional, Ponikowski, Piotr, additional, Barbato, Emanuele, additional, Rosano, Giuseppe M.C., additional, and Metra, Marco, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results